Pulse Biosciences Files 8-K

TL;DR

Pulse Biosciences filed an 8-K on 12/23/24, mostly routine filings.

AI Summary

On December 23, 2024, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material event detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Miami, Florida.

Why It Matters

This 8-K filing indicates Pulse Biosciences is providing updates or submitting required financial documents to the SEC, which is standard corporate reporting.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any significant new risks or material adverse events.

Key Numbers

• 001-37744 — Commission File Number (SEC identifier for Pulse Biosciences, Inc.)
• 46-5696597 — IRS Employer Identification No. (Tax identification for Pulse Biosciences, Inc.)

Key Players & Entities

• Pulse Biosciences, Inc. (company) — Registrant
• December 23, 2024 (date) — Date of Earliest Event Reported
• Delaware (jurisdiction) — State of Incorporation
• Miami, Florida (location) — Address of Principal Executive Offices
• 510-906-4600 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
• $0.01 — ubject to redemption by the Company for $0.01 per underlying share of common stock, o
• $16.50 — exercise price for the Warrants (i.e., $16.50), subject to adjustment, per whole shar

Filing Documents

• plse20241223_8k.htm (8-K) — 24KB
• ex_760490.htm (EX-99.1) — 12KB
• 0001437749-24-038302.txt ( ) — 170KB
• plse-20241223.xsd (EX-101.SCH) — 3KB
• plse-20241223_def.xml (EX-101.DEF) — 11KB
• plse-20241223_lab.xml (EX-101.LAB) — 15KB
• plse-20241223_pre.xml (EX-101.PRE) — 11KB
• plse20241223_8k_htm.xml (XML) — 3KB

01

Item 8.01 Other Events. On December 23, 2024, Pulse Biosciences, Inc. (the "Company") issued a press release announcing that it will deliver an irrevocable election to redeem certain of the outstanding common stock warrants issued on July 3, 2024 ("Warrants") in connection with the Company's rights offering pursuant to its Registration Statement on Form S-3, as amended (File No. 333-278494), as modified by the post-effective amendment filed with the U.S. Securities and Exchange Commission (the "SEC") on May 28, 2024 (the "Rights Offering"). The irrevocable election will concern only the first half of the Warrants issued by the Company in the Rights Offering (CUSIP # 74587B135), which are subject to redemption by the Company for $0.01 per underlying share of common stock, on not less than thirty (30) days' written notice, if the volume weighted average price of the Company's common stock equals or exceeds 150% of the exercise price for the Warrants (i.e., $16.50), subject to adjustment, per whole share, for twenty (20) consecutive trading days (hereinafter referred to as the "150% Warrants"). Outstanding 150% Warrants may be exercised for cash in accordance with the terms therein, at any time prior to 6:30 p.m., Eastern Time, on February 5, 2025, the redemption time and date for the 150% Warrants. Any 150% Warrants that are not exercised on or before the redemption time will be redeemed by the Company for $0.01 per warrant share. A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of Pulse Biosciences, Inc. dated December 23, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: December 23, 2024 By: /s/ Kevin P. Danahy Kevin P. Danahy Chief Commercial Officer (Principal Executive and Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR